Precision Medicine Podcast · Trapelo

New Legislation Helps Deliver Appropriate Biomarker Testing to More Cancer Patients When and Where They Need It

·38 min·2 clips
Hilary says 71% of people in the largest plan in each state were covered by policies more restrictive than NCCN guidelines.
Karen Cushman sets the stage by focusing on a gap that can open up after a cancer diagnosis: the delay or denial of biomarker testing that could shape treatment choices. Hilary G. Geckner joins as Director of State and Local Campaigns for ACS CAN, and Christine Ashcraft joins as founder and president of uScript and a longtime precision medicine voice. The conversation centers on how public policy is shaping access to precision medicine in the United States. ACS CAN's work is presented as a response to a real insurance problem, not a theoretical one. Payers may point to clinical practice guidelines without really following them, even while saying they consult them. That mismatch can leave patients waiting for testing that should already be part of their care. The guests describe how ACS CAN worked with a wide mix of patient and provider groups to develop legislative language for the states. The goal is to bring insurance coverage policies in line with the latest evidence. The episode notes that the legislation, now law in 20 different states, draws on outside evidence sources. Those sources include FDA-approved and cleared tests and labeled indications. The discussion also makes room for the fact that science keeps moving. Coverage written as if the field were fixed in 2024 would not serve patients for long. The guests stress that policies need to stay current as new breakthroughs arrive. They also point to clinical practice guidelines such as NCCN and CPIC as part of the evidence base. The point is not simply to add more rules. It is to make sure patients can get the right test at the right time. The conversation stays focused on how coverage decisions affect real access, not just how they look on paper. It ends by returning to the broader question of where the states stand and why the work still matters.

As heard by us

Policy, testing, and coverage come together in a clear look at how precision medicine reaches patients.

Biomarker testing sits at the center of this episode, and the policy angle stays grounded in that reality. Karen Cushman keeps the discussion practical while Hilary G.

Read the full review in PlayNext →

Why you'd press play

Want the policy behind better cancer testing, without the jargon pileup?

Read the full recommendation in PlayNext →
Listen to the show on